Sprint Bioscience appoints new CEO

Sprint Bioscience announces Erik Kinnman as new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry.

“We are very pleased to welcome Erik Kinnman as the new CEO of Sprint Bioscience. His extensive experience from leading positions in global pharmaceutical companies, solid scientific background, and thorough understanding of the capital market give him excellent qualifications to lead the company in its further development. I would also like to extend a big thank you to Charlotte Leife for her significant efforts during her time as Acting CEO”, says Sprint Biosciences’ Chairman of the Board, Rune Nordlander.

Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021.

Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive), a biotechnology company listed on Nasdaq Stockholm’s Main Market. Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank. Erik Kinnman is a physician, Doctor of Medicine, and associate professor at Karolinska Institutet. He has a specialist education in neurology and pain relief, as well as an Executive MBA from the Stockholm School of Economics.

More information in this press release.

“Soon we can meet again IRL”

Since the Covid outbreak, our work has been characterised by video meetings, especially in our various focus groups. Success has exceeded expectations, thanks to the fact that the approximately 70 people who are involved in the groups had time to get to know one other and the issues even before the pandemic. But we are really looking forward to being able to meet again IRL, and hopefully soon – it is so much more enjoyable!

XNK Therapeutics lays the groundwork for GMP facility in Flemingsberg

"Flemingsberg is the place in the world you want to be if you work with NK cells. There is a strong research facility here with a world-leading research group and proximity to a clinic that really knows NK cells. We recently started the construction of a new GMP facility with an associated research laboratory of 350 square meters for our NK cell therapy. The new facility is being built at Novum in Flemingsberg and, once the facility is completed in 2022, it will give us complete control over the entire development chain."

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

PRENUMERERA

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

PRENUMERERA
CF_logo_neg
2021-03-12T10:47:22+01:00
Go to Top